Baxkh & Sastimos LLC unites advanced bio-active peptide chemistry, MoCRA compliant cosmetic assets, 503B sterile compounding infrastructure, and licensed clinical delivery networks.
GLOBAL HEALTHCARE PARTNERS
Formed as a Texas limited liability corporation, Baxkh & Sastimos LLC develops transformative medical and aesthetic technologies designed to eliminate patient trauma, optimize clinical delivery, and establish nationwide sterile synthesis capability.
Texas limited liability company with complete operational, financial, regulatory, and IP isolation guided by specialized healthcare legal counsel.
100% Retained Enterprise IPLow-overhead presence at UTMB Customs House Incubator (1700 Strand St) for reduced startup expenses and collaboration.
Low Capital Intensity SetupBlends immediate MoCRA compliant cosmetic cash flow, personal investments and non-dilutive grant funding.
$605.68M 5-Yr Gross Revenue RampA fully integrated life sciences ecosystem spanning fast-to-market cosmetics, high-value prescription biologics, licensed clinical delivery, and in-house cGMP manufacturing.
FDA Section 505(b) NDA prescription candidates priced competitively per treatment course (benchmarked against $20,000+ injectables), delivering 99.8%+ gross profit margins and Numerology 8 verification ($15,200 -> 1+5+2+0+0=8).
Projects: Phoenix, Aegis, Prism, MotusImmediate cash-flow engine distributed to licensed estheticians and medspas in boxes of 10 sterile 5ml glass vials for microneedling glide paired with 30ml retail companion drops.
Year 1 Launch | 92.1% Net MarginManagement Services Organization (MSO) and Clinical Trial Agreement (CTA) framework enabling partner wellness centers to deliver licensed protocols administered by MDs, DOs, NPs, PAs, and Estheticians.
CPOM & Anti-Fee Splitting CompliantYear 3 $4.8M ISO 5/7 cleanroom buildout (USP <797>/<800> compliant), cutting raw peptide COGS by 85% to $0.45/unit, supplying 503B wholesale preparations, and conducting blood-brain barrier (BBB) permeability R&D.
Cuts COGS 85% | $40M Wholesale RevSpecific chemical formulations and amino acid sequences are strictly protected under Mutual NDA. Public descriptors reflect indication targets and high-level class.
Bioresorbable matrix engineered for acute dermal trauma, eliminating mechanical friction and providing antimicrobial shielding against systemic sepsis.
Quad-active topical bio-gel targeting chronic inflammatory dermal conditions, providing non-steroidal immune-modulation benchmarked against $20k+ injectables.
Triple-active matrix targeting localized restoration and dermal autoimmune destruction.
Dual-action bio-matrix stimulating smooth muscle contraction and targeted mucosal recovery for severe gastrointestinal motility stagnation.
Phased commercial rollout balancing immediate cash flow, clinical MSO expansion, in-house 503B synthesis buildout, and high-value biologic Rx commercialization.
$1.28M Revenue
Esthetician microneedling glide & retail drops launch. Immediate cash flow.
$8.80M Revenue
MSO rollout, GLP porcine burn trials, and Pre-IND filings.
$38.80M Revenue
$4.8M ISO 5/7 cleanroom construction & FDA 503B registration.
$148.80M Revenue
In-house synthesis cuts COGS 85% to $0.45/unit + $20M wholesale.
$408.00M Revenue
Full commercial launch of $15,200/course Rx biologics. $392.7M net profit.
5-Year Cumulative Gross Revenue: $605,680,000 | Cumulative Net Profit: $568,540,000
Access SBDC master business plans, 5-year financial models, 503B roadmaps, download our mutual NDA, and schedule an executive briefing with founders James Miller and Kate Wilson.
Required prior to receiving full proprietary formulation data and UTMB licensing specifications.
⬇️ Download Mutual NDA (PDF)Complete SBDC-compliant master business plan covering 4-pillar architecture and regulatory roadmap.
📊 Download Business Plan (PDF)Phased commercial execution from MoCRA Babu launch to Year 3 $4.8M cleanroom buildout.
🗺️ Download 5-Year Strategy (PDF)1-Page high-value biologic briefing sheet featuring $15,200 Rx pricing and 99.4% gross profit margins.
📑 Download Executive Brief (PDF)Master WBS, 36-month milestone schedule, and risk management controls.
⚙️ Download PM Execution Plan (PDF)Esthetician sales sheet, microneedling glide protocols, and wholesale pricing structures.
🧴 Download Babu Sales Guide (PDF)Book a direct 30-minute consultation with founders James Miller (Executive Director) and Kate Wilson (Managing Director).
Steered by experienced Texas entrepreneurs dedicated to advancing medical innovation and regional economic development.
Leading operational strategy, legal compliance, corporate structuring, and commercialization pathways for Baxkh & Sastimos LLC.
Spearheading life sciences strategy, clinical partnerships, IP development, and incubator resource integration across the Texas coast.
We welcome strategic healthcare partnerships, clinical inquiries, investment dialogues, and grant collaborations.
One or two emails a month. No spam, unsubscribe with one click.
